Testing ENV-294 for moderate-to-severe atopic dermatitis
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You've had atopic dermatitis (eczema) for at least 12 months
- Your eczema is moderate to severe and covers at least 10% of your body
- You've tried other eczema treatments (topical steroids, creams, or systemic medications) without good results in the past 6–12 months
- You have significant itching (score of 4 or higher on a standard scale)
- You agree to use a basic moisturizer daily throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.